Novo Nordisk’s Clinical Momentum Collides with Stubborn Share Price as Longevity Ambitions Take Shape

Semaglutide shows 52% sleep apnea risk reduction and anti-aging signals, but Novo Nordisk shares remain down 44% amid market focus on competition and near-term catalysts.

The chasm between clinical progress and market reception is widening for Novo Nordisk. Despite a flurry of positive data presented at the American Diabetes Association conference in New Orleans — spanning sleep apnea, asthma, and even biological aging — the stock remains stuck near multi-year lows, down almost 44% over the past twelve months.

Semaglutide 2.4 mg continues to demonstrate a therapeutic breadth that goes far beyond weight loss. New analyses from the SELECT and STEP trials show the drug slashed the risk of sleep apnea by 52% and reduced asthma-related complications by 42%. Systolic blood pressure dropped by an average of 5.48 mmHg, and positive signals were also observed in the liver disease MASH. Researchers presented evidence that the drug may lower the biological age of the heart and kidneys, with mortality benefits appearing independently of weight reduction.

Chief executive Mike Doustdar used the ADA platform to signal a strategic pivot that would recast Novo Nordisk as a broad cardiometabolic and longevity platform. He confirmed that the company is actively exploring applications in aesthetic medicine, joint inflammation, and anti-aging — fields where competition is thinner. Asked about investments in skin care or hair-loss treatments, Doustdar answered with an unequivocal “yes.”

Meanwhile, the commercial rollout of the oral Wegovy tablet is gaining speed. The pill crossed three million prescriptions in just over five months in the US, making it one of the strongest pharmaceutical launches by volume in recent memory. International expansion begins in the second half of 2026, with the United Arab Emirates already granting approval.

On the pipeline front, the combination therapy CagriSema — a dual blend of cagrilintide and semaglutide — delivered a 14.2% weight reduction in type 2 diabetes patients, results published simultaneously in The Lancet. The FDA is expected to rule on the drug in the fourth quarter of 2026, a decision the company hopes will provide the first concrete catalyst in months. Also in the second half of the year, Novo Nordisk will launch a “Medicare GLP-1 Bridge” programme in the US, capping monthly out-of-pocket costs at $50 for eligible patients starting July 1.

Yet none of this has lifted the stock. At around €36.84, the shares remain nearly 47% below their 52-week high of €70.13. The market appears to be discounting the pipeline promise and focusing instead on competitive pressures and the lack of a near-term earnings catalyst. A positive FDA verdict on CagriSema could shift that calculus, but until then the disconnect between lab and trading floor persists.